Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying

Published 27/02/2024, 12:10
Updated 27/02/2024, 13:40
© Reuters.  Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

The Dow Jones index closed lower by over 50 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

AmeriServ Financial

  • The Trade: AmeriServ Financial, Inc. (NASDAQ: ASRV) Director Richard W. Bloomingdale acquired a total of 1,783 shares an average price of $2.85. To acquire these shares, it cost around $5,086.
  • What’s Happening: On Jan. 23, AmeriServ Financial posted a loss for the fourth quarter.
  • What AmeriServ Financial Does: AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services.
Dakota Gold
  • The Trade: Dakota Gold Corp. (NYSE: DC) Director Alice D. Schroeder acquired a total of 7,410 shares at at an average price of $1.96. To acquire these shares, it cost around $14,521.
  • What’s Happening: On Feb. 21, Dakota Gold announced additional results for twelve drill holes from the Richmond Hill Gold Project.
  • What Dakota Gold Does: Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 40 thousand acres surrounding the historic Homestake Mine.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Galera Therapeutics

  • The Trade: Galera Therapeutics, Inc. (NASDAQ: GRTX) 10% owner Yair Schneid acquired a total of 932,402 shares at an average price of $0.18. The insider spent around $166,417 to buy those shares.
  • What’s Happening: On Nov. 14, Galera Therapeutics posted a narrower-than-expected third-quarter loss.
  • What Galera Therapeutics Does: Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.